DENTSPLY SIRONA (XRAY) AI Stock Analysis

DENTSPLY SIRONA

(BMV:XRAY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Cash GenerationPositive operating and free cash flow provide internal funding for operations and selected investments despite reported losses. This resilience can support liquidity over the next several quarters, although the lower free cash flow versus earlier periods means cash generation has not fully resolved the broader earnings pressure.

Negative Factors

Revenue and Profitability PressureMulti-year revenue contraction combined with a deeply negative TTM net margin indicates that the business has not yet restored sustainable earnings power. Persistent losses reduce reinvestment flexibility and make future improvement dependent on successful recovery in demand, execution and operating costs.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Tech...

DENTSPLY SIRONA Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.

Positive Updates

Revenue and EPS Stability (Non-GAAP)

Q2 revenue of $898 million; adjusted EPS flat year-over-year at $0.52. Adjusted EBITDA margins were approximately flat YoY despite headwinds.

Negative Updates

Top-Line Decline

Total Q2 revenue declined 4.1% as reported and 6.3% on a constant currency basis. After adjusting for Byte and a planned ~$8 million dealer inventory reduction, revenue declined 3.6% on a constant currency basis.

Company Guidance

The company maintained its 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50 (explicitly excluding the $44 million tariff refund and any incremental tariff impacts), while noting Q3 revenue should decline sequentially due to seasonality and Q3 earnings are expected below Q2 2026 levels excluding the $0.17 per‑share tariff refund benefit; Q2 results included $898 million of revenue (down 4.1% reported, down 6.3% constant currency, and down 3.6% CC after adjusting for Byte and a planned ~$8 million dealer inventory reduction), adjusted EPS of $0.52 (flat year‑over‑year), roughly flat adjusted EBITDA margins, operating cash flow of $99 million versus $48 million prior year, a $44 million tariff refund (≈$0.17/share) that enabled opportunistic repurchases of 1.3 million shares for ≈$12 million (average price below $10), ending cash of $239 million and net debt/EBITDA of 3.2x, and management said it expects the payoff from investments in sales, clinical education and R&D to become increasingly visible beginning in Q4.

DENTSPLY SIRONA Risk Analysis

DENTSPLY SIRONA disclosed 26 risk factors in its most recent earnings report. DENTSPLY SIRONA reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

DENTSPLY SIRONA Peers Comparison

Overall Rating

Financial Indicators

MX:XRAY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

DENTSPLY SIRONA AI Stock Analysis